Zydus receives final approval from the USFDA for Ambrisentan Tablets

Zydus receives final approval from the USFDA for Ambrisentan Tablets _________________________________________________________ Ahmedabad, 29 March, 2019 Zydus Cadila has received the final approval from the USFDA to market Ambrisentan Tablets USP (US RLD – Letairis Tablets), 5 mg and 10 mg. It is used to treat high blood pressure in the lungs (pulmonary arterial hypertension) and will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The US sales of Ambrisentan Tablets USP stood at $ 943 million in 2018. The g roup now has 258 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗